Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 12/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10696084 | 1.00 | ACE (0.45) | ACELMNASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL9863834 | 0.91 | ACE (0.42) | ACELMNASMN1; SMN2 | |
| SCHEMBL10825140 | 0.86 | ACE (0.39) | ACELMNASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL10825128 | 0.86 | ACE (0.39) | ACELMNASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL3369565 | 0.80 | DPP8 (0.38) | ACELMNASMN1; SMN2CYP1A2POLB | |
| SCHEMBL10885324 | 0.80 | HPGD (0.36) | ACELMNASMN1; SMN2POLBMEN1 | |
| SCHEMBL6619629 | 0.80 | DPP8 (0.38) | ACELMNASMN1; SMN2CYP1A2POLB | |
| SCHEMBL11199706 | 0.80 | ABCB11 (0.37) | ACELMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL9864211 | 0.79 | ALDH1A1 (0.39) | ACEALDH1A1 | |
| SCHEMBL10789661 | 0.79 | ALDH1A1 (0.39) | ACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0551927-B1 | Method for the treatment of cardiac insufficiency | HOECHST AG (DE) | 1998-09-23 | — | — | EP | disclosed |
| US-5747504-A | ADMINISTERING N-ALANYL-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES AS HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-05 | — | — | US | disclosed |
| US-5744496-A | Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-04-28 | — | — | US | disclosed |
| US-5684016-A | Method of treating cardiac insufficiency | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-04 | — | — | US | disclosed |
| US-5403856-A | Method of treating cardiac insufficiency using angiotensin-converting enzyme inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-04 | — | — | US | disclosed |
| EP-0158927-B1 | Process for the treatment of heart failure | HOECHST AG (DE) | 1993-12-08 | — | — | EP | disclosed |
| EP-0551927-A1 | Method for the treatment of cardiac insufficiency | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-21 | — | — | EP | disclosed |
| EP-0158927-A2 | Process for the treatment of heart failure | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-10-23 | — | — | EP | disclosed |